C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
IGC Equity

IGC

OTCMKTS · IGC

$0.30
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
40/100 composite
Fundamentals38
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

India Globalization Capital (IGC) currently holds a Neutral rating within the 40.0 composite band. This reflects moderate conviction given a score of 3 out of 5. The strongest contributions to this composite arise from the regulatory pillar, which surpasses others like fundamentals, market, and editorial at 49.0. The strength in regulatory adherence is offset by challenges in fundamentals and editorial coverage, resulting in an overall cautious stance.

Looking closer at IGC's financials, the company faces difficulties with revenue contraction and negative operating margins, indicating ongoing profitability challenges. Year-over-year revenue growth is down, while gross margins remain relatively solid, suggesting potential pricing discipline. However, operating as well as EBITDA margins remain deep in the negative territory, contributing to a "stretched" financial condition that challenges liquidity. Importantly, these figures demonstrate a mismatch between ongoing expenses and revenue generation. The firm’s market capitalization remains at a lower tier, further emphasizing the financial stretch but suggests potential volatility due to market scale.

Regulatory stability signifies a crucial positive for IGC, particularly as there have been no enforcement actions in recent periods, which reinforces confidence in compliance with US jurisdiction standards. Absent recent regulatory events reflects stability within an otherwise volatile industry. Attention should be directed toward IGC's future operations, particularly around regulatory filings, to help solidify investor sentiment. These filings will serve as critical insights into the firm's compliance posture and enable further evaluation of its positioning in the regulatory landscape. Moreover, consistent adherence to regulatory expectations will potentially provide the necessary buffer to navigate financial challenges and bolster investor confidence.

Scored: 2026-08-25Valid through: 2026-10-09Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
10224 FALLS ROAD, POTOMAC, MD, 20854
Phone
301-529-4996
CEO
Ram Mukunda
CFO
Claudia Grimaldi
SEC CIK
1326205
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$28.4M
Enterprise value
$29.1M
Price to book
4.64
Price to sales
25.67
EV / EBITDA
27.31
Revenue (TTM)
$1.1M
Gross profit (TTM)
$511K
EBITDA
$-7.5M
Operating margin
-722.7%
Profit margin
0.0%
Rev growth YoY
-3.9%
Return on equity
-83.3%
Return on assets
-50.3%
EPS (TTM)
$-0.06
EPS est. current year
$-0.08
Wall St. target price
$4.25
Shares outstanding
104.4M
Insider ownership
13.4%
Institutional ownership
21.7%
Beta
0.46
Full-time employees
70
GICS sector
Healthcare
GICS industry
Biotechnology
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for IGC (IGC)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for IGC (IGC), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for IGC are maintained by Cannabis Investor News and refreshed throughout the trading day.